

Correspondence

Reply

To the Editor:

We thank Nanayakkara et al¹ for the comments on and interest in our article.² We in this reply focus on (1) diameter of air particles that affects pollinosis, (2) lead levels of the purchased cedar pollens collected from the tree before dispersion in Table E4, and (3) pathological modification of nasal mucosa in subjects with allergic rhinitis (Fig E5).

Air particles of less than or equal to 2.5 μm in diameter ($\text{PM}_{2.5}$) can reach the lower airway through the upper airway, whereas those of more than 10 μm in diameter including cedar pollen particles of about 40 μm in diameter¹ are trapped in the upper airway. We disagree with the calculation of intranasal lead level by Nanayakkara et al without considering the sizes of air particles that pass through the nasal cavity.¹ In this reply, we first consider a source of intranasal lead with focus on air particles of more than 10 μm in diameter that can be trapped in the nasal cavity.

There is a positive correlation between lead level in nasal epithelial lining fluid (ELF) and dispersed pollen counts (Table II), indicating that increased lead level in ELF is partially dependent on dispersed pollens. However, the source of intranasal lead in ELF remains unknown. Lead level of air particles of more than 10 μm in diameter account for only less than 2% of the total lead concentration in all air particles,³ indicating that more than 98% of lead in air particles can pass through the nasal cavity. Furthermore, pollens can adhere to air particles of less than or equal to 10 μm in diameter, known as suspended particulate matters (SPMs), including heavy metals during dispersion.⁴ These results indicate that increased lead level of pollen through dispersion as well as the limited lead level of large air particles that are trapped in the nasal cavity should be considered for estimation of the contribution of lead in air particles to the lead level in ELF.

Nanayakkara et al¹ estimated the intranasal lead level by purchased pollens before dispersion (Table E4). Following their method of calculation, we propose another hypothesis considering the increased lead level of pollen through dispersion.¹ Weights of SPMs of 10 μm in diameter and standard density are approximately 5.2×10^{-10} g. One gram of SPMs contains 850×10^3 ng/g lead.⁵ If a pollen adheres to 3 SPMs through dispersion, the lead level in the pollen could be estimated as 0.17 ng/m^3 ($125 [\text{grain/m}^3] \times 5.2 \times 10^{-10} [\text{g/particle}] \times 3 [\text{particle}] \times 850 \times 10^3 [\text{ng} \cdot \text{Pb/g} \cdot \text{SPM}]$).⁵ The maximum concentration of air particles of more than 10 μm in diameter could be 0.4 ng/m^3 ($20 \text{ ng/m}^3 \times 2/100$ [2%]). The maximum lead level per day that is accumulated in the nasal cavity of patients with allergy is estimated to be 12.3 ng ($[0.17 \text{ ng/m}^3 + 0.4 \text{ ng/m}^3] \times 21.6 \text{ m}^3$ [air volume of respiration per day]). The estimated level is roughly comparable to the increased lead level in ELF from pre-season to season in patients with allergy (Fig 1, A). Thus, SPMs containing a higher lead level, which intrinsically pass through the nasal cavity, may come to be trapped in the nasal cavity by adhesion of SPMs to pollens during dispersion. This is our suggested mechanism of the increased intranasal level of lead

partially derived from pollen. Further study on the lead level of dispersed pollens is needed to more strictly elucidate the origin of intranasal lead.

Nanayakkara et al considered intranasal lead level on the basis of volume of nasal mucosal mucus and nasal mucociliary clearance time in healthy subjects.¹ Although the review of pathologic factors of allergic subjects as well as environmental factors is important for our allergotoxicologic analysis, they overlooked the pathological differences including the volume of nasal mucosal mucus and nasal mucociliary clearance time between healthy subjects without allergy and subjects with allergy. Moreover, our results in model mice indicate 7-fold and 4.7-fold increased goblet cell number and mucins in nasal mucosa, respectively, in allergic mice treated with an antigen and lead compared with those in nonallergic mice with no treatment (Fig E5). Lead has been reported to be accumulated in goblet cells and mucins in the small intestine.⁶ These results suggest that the pathological modification induced by coexposure to an antigen and lead in nasal mucosa of allergic subjects further increases the intranasal lead level in allergic subjects.

Our model mice with allergic rhinitis were treated with liquid lead nitrate but not air particles including lead. A different method for exposure to lead may differently affect the accumulated level of intranasal lead. However, lead concentration in murine ELF (13.7 $\mu\text{g/mL}$) was comparable to that in human ELF (27.2 $\mu\text{g/mL}$). These results suggest that the treated lead dose is physiologically acceptable to observe the effects of lead on the pathogenesis of allergic rhinitis.

Finally, we appreciate the comments by Nanayakkara et al on lead concentrations in urine samples.¹ Because of our error in calculation, lead concentrations in urine samples were expressed as 100-fold higher than the correct values in Fig 1, C, and Table E1. The article in press version showed those errors, but the final published article has the correct Fig 1, C, and Table E1.²

Takumi Kagawa, MMSc^{a,b}

Akira Tazaki, PhD^{a,b}

Huadong Xu, MPH^{a,b}

Nobutaka Ohgami, PhD^{a,b}

Masashi Kato, MD, PhD^{a,b}

From ^athe Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine, and ^bVoluntary Body for International Healthcare in Universities, Nagoya, Japan. E-mail: katomasa@med.nagoya-u.ac.jp.

This study was supported in part by Grants-in-Aid for Scientific Research (A) (grant nos. 15H01743, 15H02588, and 19H01147), (B) (grant nos. 17KT0033 and 20H03929), (C) (grant no. 16K08343), and Challenging Exploratory Research (grant no. 20K21708) from the Ministry of Education, Culture, Sports, Science and Technology; Mirai-Program Small Start Type from the Japan Science and Technology Agency; and Kobayashi International Scholarship Foundation and AEON Environmental Foundation.

Disclosure of potential conflict of interest: T. Kagawa has received scholarship from the Convolution of Informatics and Biomedical Sciences on Global Alliances from the Ministry of Education, Culture, Sports, Science and Technology. A. Tazaki has received grants from the Ministry of Education, Culture, Sports, Science and Technology. H. Xu has received scholarship from the China Scholarship Council. N. Ohgami has received grants from the Ministry of Education, Culture, Sports, Science and Technology. M. Kato has received grants from the Ministry of Education, Culture, Sports, Science and Technology, the Japan Science and Technology Agency, the Kobayashi International Scholarship Foundation, and the AEON Environmental Foundation.

REFERENCES

1. Nanayakkara S, Yamamoto N, Harada K. Intranasal level of lead estimated from airborne pollen and urinary lead levels in Japan. *J Allergy Clin Immunol* 2021; 148 XXX-XXX.
2. Xu H, Ohgami N, Sakashita M, Ogi K, Hashimoto K, Tazaki A, et al. Intranasal levels of lead as an exacerbation factor for allergic rhinitis in humans and mice. *J Allergy Clin Immunol* 2021;139-47.
3. Allen AG, Nemitz E, Shi JP, Harrison RM, Greenwood JC. Size distribution of trace metals in atmospheric aerosols in the United Kingdom. *Atmospheric Environ* 2001; 35:4581-91.
4. Visez N, Ivanovsky A, Roose A, Gosselin S, Sénéchal H, Poncet P, et al. Atmospheric particulate matter adhesion onto pollen: a review. *Aerobiologia* 2020;36: 49-62.
5. Khan MF, Hirano K, Masunaga S. Quantifying the source of hazardous elements of suspended particulate matter aerosol collected in Yokohama, Japan. *Atmospheric Environ* 2010;44:2646-57.
6. Tomczok J, Grzybek H, Sliwa W, Panz B. Ultrastructural aspects of the small intestinal lead toxicology. *Exp Pathol* 1988;35:93-100.

<https://doi.org/10.1016/j.jaci.2021.05.025>